Group 1 - Calidi Biotherapeutics, Inc. has priced its public offering of 5,000,000 shares of common stock at 4.25 million before fees and expenses [1][2] - The offering is being conducted under a shelf registration statement declared effective by the SEC on October 10, 2024, and will be made only by means of a written prospectus [3] - The company intends to use the net proceeds from the offering for working capital and general corporate purposes [2] Group 2 - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted immunotherapies using proprietary technology that enhances the immune system's ability to fight cancer [5] - The company utilizes allogeneic stem cells to deliver oncolytic viruses for treating various oncology indications, including high-grade gliomas and solid tumors [5] - Calidi's dual approach aims to treat or prevent metastatic disease through its preclinical off-the-shelf enveloped virotherapies [5]
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock